ClinicalTrials.gg
CompletedNCT04209634Updated Aug 29, 2025Results posted

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

A Phase 2/3 interventional study of Pozelimab in CD55-deficient Protein-losing Enteropathy and CHAPLE, sponsored by Regeneron Pharmaceuticals. Completed at 3 sites in 3 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Study summary

The primary objective of the study is to determine the effect of pozelimab on active CD55-deficient protein-losing enteropathy (PLE; CHAPLE).

The secondary objectives of the study are:

  • To evaluate the safety and tolerability of pozelimab in patients with CD55-deficient PLE disease
  • To evaluate the effect of pozelimab on CD55-deficient PLE (both patients with active disease at baseline and those with inactive disease on eculizumab, switching to pozelimab)
  • To determine the effects of pozelimab on albumin and other serum proteins (total protein, immunoglobulins)
  • To determine the effects of pozelimab on ascites
  • To determine the effects of pozelimab on stool consistency
  • To determine the effect of pozelimab on health-related quality of life
  • To determine the effect of pozelimab on lab abnormalities observed in CD55-deficient PLE such as hypertriglyceridemia, thrombocytosis, and hypovitaminosis B12
  • To describe the effects of pozelimab on the sparing of concomitant medications and reduction in hospitalization days
  • To determine the effects of pozelimab on growth
  • To characterize the concentration of pozelimab in patients with CD55-deficient PLE
  • To assess the incidence of treatment-emergent ADA for pozelimab in patients with CD55-deficient PLE disease
02

Conditions studied

  • CD55-deficient Protein-losing Enteropathy
  • CHAPLE

Keywords

  • CD55-deficient PLE
  • complement hyperactivation, angiopathic thrombosis, protein-losing enteropathy (CHAPLE disease)
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of CD55-deficient PLE/CHAPLE disease (based on a history of PLE), confirmed by biallelic CD55 loss-of-function mutation detected by genotype analysis
  • Active disease as defined by the protocol or inactive disease on eculizumab therapy (and whose treating physician has the expectation of future access to renewed eculizumab treatment should this be required), and is willing to discontinue eculizumab during screening and start pozelimab at baseline with no eculizumab wash-out

Key Exclusion Criteria:

  • History of meningococcal infection
  • No documented meningococcal vaccination within 3 years prior to screening and patient unwilling to undergo vaccination during the study
  • No documented vaccination for Haemophilus influenzae and Streptococcus pneumoniae if applicable based on local practice or guidelines prior to screening and patient unwilling to undergo vaccination during the study if required per local practice or guidelines
  • Presence of a concomitant disease that leads to hypoproteinemia at the time of starting pozelimab
  • A concomitant disease that leads to secondary intestinal lymphangiectasia such as a fontan procedure for congenital heart disease

Note: Other protocol-defined Inclusion/Exclusion criteria apply.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Active PLE

    Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease

    Drug: Pozelimab

Interventions

  • Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.

    Also known as: REGN3918

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24

    Normalization of serum albumin was defined as serum albumin within the normal range at least 70 percent (%) of measurements between weeks 12 and 24, and no single albumin measurement of \<2.5 grams per deciliter (g/dL) between weeks 12 and 24, and no requirement for albumin infusion between weeks 12 and 24. Improvement in the following 4 prespecified clinical outcomes that were evaluable for improvement at baseline, without worsening of the others: Daily bowel movement frequency, the presence and severity of facial edema (physician-reported), the presence and severity of peripheral edema (physician-reported), and the participant/caregiver assessment of frequency of problematic abdominal pain. Percentage of participants with active disease at baseline who achieved normalization of serum albumin and improvement in prespecified clinical outcomes at Week 24 were reported.

    Time frame: At Week 24

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs

    TEAEs are defined as AEs that developed or worsened during the on-treatment period. The on-treatment period is defined as the time from first dose of investigational product up to 21 weeks after the last dose of investigational product. Severity of TEAEs was graded according to the following scale: Mild: Does not interfere in a significant manner with the patient's normal functioning level, Moderate: Produces some impairment of functioning but is not hazardous to health and Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participants health.

    Time frame: From start of study drug administration up to approximately 144 weeks

  2. Number of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 24

    Improvement in most bothersome sign/symptom determined using semi-structured concept elicitation interview, from 'core' clinical endpoints of frequency of bowel movements, peripheral edema, facial edema, abdominal pain frequency, nausea, vomiting, stool consistency.

    Time frame: At Week 24

  3. Number of Bowel Movements Per Day Based on a 1-week Average up to Week 24

    Daily bowel movements captured by e-diary. The number of bowel movements per day was calculated each week of the study. It was based on a 1-week average and calculated as the sum of the number of bowel movements in a given week divided by the number of days with non-missing bowel movement frequency data. If more than 3 days of bowel movement data was missing in a given week, bowel movement frequency data was considered missing for that week.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24

  4. Number of Days Per Week With >=1 Bowel Movement of Loose/Watery Stool Consistency at Week 24

    The number of days per week with \>=1 loose/watery bowel movement, is calculated each week of the study as the sum of the number of days with \>=1 loose/watery bowel movement in a given week divided by the number of days with non-missing stool consistency data and then multiplied by 7, is presented. If more than 3 days of stool consistency data was missing in a given week, stool consistency data was considered missing for that week.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24

  5. Number of Participants With Abdominal Ascites at Week 24

    The measurement of abdominal ascites (excess abdominal fluid) was based on abdominal circumference. Abdominal circumference was measured regardless of the physician's assessment of the presence or absence of ascites.

    Time frame: Baseline up to Week 24

  6. Absolute Value of Albumin at Specified Timepoints up to Week 24

    Blood samples were collected from participants at defined time points for the assessment of albumin. Absolute value of albumin at specified timepoints was reported.

    Time frame: Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24

  7. Absolute Values of Protein, and Immunoglobulin G (IgG) at Baseline and Week 24

    Blood samples were collected from participants at defined time points for the assessment of protein and IgG. Absolutes values of protein and IgG measured as g/L at baseline and Week 24 was reported.

    Time frame: Baseline, Week 24

  8. Absolute Values of Immunoglobulin (Ig), Immunoglobulin M (IgM), and Immunoglobulin A (IgA) at Baseline and Week 24

    Blood samples were collected from participants at defined time points for the assessment of Ig, IgM and IgA. Absolute value of Ig, IgM and IgA measured as mg/dL at baseline and Week 24 was reported.

    Time frame: Baseline, Week 24

  9. Absolute Values of Vitamin B12 at Baseline and Week 24

    Blood samples were collected from participants at defined time points for the assessment of vitamin B12. Absolute values of vitamin B12 at baseline and Week 24 was reported.

    Time frame: Baseline, Week 24

  10. Absolute Values of Iron and Unsaturated Iron Binding Capacity at Baseline and Week 24

    Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of unsaturated iron and unsaturated iron binding capacity measured as micromoles per liter (mcmol/L) at baseline and Week 24 was reported.

    Time frame: Baseline, Week 24

  11. Absolute Values of Vitamin B9 up to Week 24

    Absolute Values of Vitamin B9 - Central Lab

    Time frame: Baseline up to Week 24

  12. Absolute Values of Ferritin at Baseline and Week 24

    Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of ferritin was reported.

    Time frame: Baseline, Week 24

  13. Absolute Values of Magnesium, Total Cholesterol, and Triglycerides at Week 24

    Blood samples were collected from participants at defined time points for the assessment of magnesium, total cholesterol, and triglycerides. Absolute values of magnesium, total cholesterol, and triglycerides measured as mmol/L at baseline and Week 24 was reported.

    Time frame: Baseline, Week 24

  14. Change From Baseline in Alpha-1 Antitrypsin Levels in Stool at Week 12 and Week 24

    Time frame: Week 12, Week 24

  15. Change From Baseline in Alpha-1 Antitrypsin Levels in Blood at Week 12 and Week 24

    Time frame: Week 12, Week 24

  16. Percentage of Participants With Active Disease at Baseline Who Maintained Disease Control

    Measured by normalization of serum albumin, no worsening of facial or peripheral edema, increase in bowel movement, or increase in abdominal pain frequency, no increase in dose of permitted concomitant medication for the treatment of PLE at any time as described in the protocol

    Time frame: Weeks 12 to 48; Weeks 12 to 144; Weeks 24 to 48; Weeks 48 to 96; Weeks 96 to 144

  17. Change From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale

    The physician assessment of facial edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).

    Time frame: Baseline and Week 144

  18. Change From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale

    The physician assessment of peripheral edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).

    Time frame: Baseline and Week 144

  19. Change From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale

    Frequency of limitations is assessed on a 5-point Likert response scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse scored and linearly transformed to a 0 to 100 scale, where lower scores indicate more frequent problems with food and drink limitations.

    Time frame: Baseline and Week 144

  20. Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the PedsQL™ Generic Core Scales

    Physical functioning, emotional functioning, social functioning, and school/work/studies functioning is assessed using a 5-point Likert scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse-scored and linearly transformed to a 0 to 100 scale, with higher scores indicating better HRQoL. The total scale score is computed as the sum of all the items over the number of items answered on individual scales. Subscale score is calculated as the sum of the items in the scale divided by the number of items answered in the scale.

    Time frame: Baseline and Week 144

  21. Number of Participants With Albumin Infusion by 24 Week Periods

    Time frame: Weeks 0 to 24; Weeks 24 to 48; Weeks 48 to 72; Weeks 72 to 96; Weeks 96 to 120; Weeks 120 to 144

  22. Change From Baseline in Albumin Values

    Time frame: Baseline and Week 144

  23. Percentage Change From Baseline in Albumin Values

    Time frame: Baseline and Week 144

  24. Time to First Normalization for Albumin Values

    Time frame: Baseline up to Week 144

  25. Change From Baseline in Protein Values

    Time frame: Baseline and Week 144

  26. Time to First Normalization for Total Protein

    Time frame: Baseline up to Week 144

  27. Change From Baseline in Immunoglobulin (Ig) Values

    Time frame: Baseline and Week 144

  28. Time to First Normalization for Ig Values

    Time frame: Baseline up to Week 144

  29. Change From Baseline in IgG Values

    Time frame: Baseline and Week 144

  30. Time to First Normalization for IgG Values

    Time frame: Baseline up to Week 144

  31. Change From Baseline in IgM Values

    Time frame: Baseline and Week 144

  32. Time to First Normalization for IgM Values

    Time frame: Baseline up to Week 44

  33. Change From Baseline in IgA Values

    Time frame: Baseline and Week 144

  34. Time to First Normalization for IgA Values

    Time frame: Baseline up to Week 144

  35. Change From Baseline in Vitamin B12 Values

    Time frame: Baseline and Week 144

  36. Time to First Normalization for Vitamin B12 Values

    Time frame: Baseline up to Week 144

  37. Change From Baseline in Vitamin B9 (Folate) Values

    Time frame: Baseline and Week 144

  38. Time to First Normalization for Vitamin B9 (Folate) Values

    Time frame: Baseline up to Week 144

  39. Change From Baseline in Iron Values

    Time frame: Baseline and Week 144

  40. Time to First Normalization for Iron Values

    Time frame: Baseline up to Week 144

  41. Change From Baseline in Unsaturated Iron Binding Capacity

    Time frame: Baseline and Week 144

  42. Time to First Normalization for Unsaturated Iron Binding Capacity

    Time frame: Baseline up to Week 144

  43. Change From Baseline in Ferritin Values

    Time frame: Baseline and Week 144

  44. Time to First Normalization for Ferritin Values

    Time frame: Baseline up to Week 144

  45. Change From Baseline in Magnesium Values

    Time frame: Baseline and Week 144

  46. Time to First Normalization for Magnesium Values

    Time frame: Baseline up to Week 144

  47. Change From Baseline in Fasting Cholesterol Values

    Time frame: Baseline and Week 144

  48. Time to First Normalization for Fasting Cholesterol Values

    Time frame: Baseline up to Week 144

  49. Change From Baseline in Fasting Triglycerides Values

    Time frame: Baseline and Week 144

  50. Time to First Normalization for Fasting Triglycerides Values

    Time frame: Baseline up to Week 144

  51. Number of Participants Who Used Concomitant Medication

    Time frame: Baseline up to Week 144

  52. Number of Hospitalization Days by 24 Week Period

    Time frame: Weeks 0 to 24; Weeks 24 to 48; Weeks 48 to 72; Weeks 72 to 96; Weeks 96 to 120; Weeks 120 to 144

  53. Change From Baseline in Body Weight Z-Score

    Weight-for-age z-score compares a participant's weight to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Body weight z-score, regardless of magnitude, represents catch-up growth.

    Time frame: Baseline and Week 144

  54. Change From Baseline in Height Z-Score

    Height-for-age z-score compares a participant's height to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Any increase in height z-score, regardless of magnitude, represents catch-up growth.

    Time frame: Baseline and Week 144

  55. Change From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50)

    Time frame: Baseline and Week 144

  56. Concentrations of Total Pozelimab in Serum

    Time frame: Baseline up to Week 164

  57. Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab

    Time frame: Baseline up to Week 164

07

Results

Posted Oct 30, 2023

Participant flow

Participant flow — Overall Study
MilestonePozelimab Injection
Started10
Completed10
Not completed0

Outcome measures

PrimaryPercentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24

Normalization of serum albumin was defined as serum albumin within the normal range at least 70 percent (%) of measurements between weeks 12 and 24, and no single albumin measurement of \<2.5 grams per deciliter (g/dL) between weeks 12 and 24, and no requirement for albumin infusion between weeks 12 and 24. Improvement in the following 4 prespecified clinical outcomes that were evaluable for improvement at baseline, without worsening of the others: Daily bowel movement frequency, the presence and severity of facial edema (physician-reported), the presence and severity of peripheral edema (physician-reported), and the participant/caregiver assessment of frequency of problematic abdominal pain. Percentage of participants with active disease at baseline who achieved normalization of serum albumin and improvement in prespecified clinical outcomes at Week 24 were reported.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24
percentage of participantsPozelimab Injection
Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24100 (74.1 to 100)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs

TEAEs are defined as AEs that developed or worsened during the on-treatment period. The on-treatment period is defined as the time from first dose of investigational product up to 21 weeks after the last dose of investigational product. Severity of TEAEs was graded according to the following scale: Mild: Does not interfere in a significant manner with the patient's normal functioning level, Moderate: Produces some impairment of functioning but is not hazardous to health and Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participants health.

Time frame:
From start of study drug administration up to approximately 144 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs
ParticipantsPozelimab Injection
Participants with TEAEs10
Participants with mild severity3
Participants with moderate severity5
Participants with severe severity2
SecondaryNumber of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 24

Improvement in most bothersome sign/symptom determined using semi-structured concept elicitation interview, from 'core' clinical endpoints of frequency of bowel movements, peripheral edema, facial edema, abdominal pain frequency, nausea, vomiting, stool consistency.

Time frame:
At Week 24
Reported as:
Count of participants · Participants
Number of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 24
ParticipantsPozelimab Injection
Number of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 2410
SecondaryNumber of Bowel Movements Per Day Based on a 1-week Average up to Week 24

Daily bowel movements captured by e-diary. The number of bowel movements per day was calculated each week of the study. It was based on a 1-week average and calculated as the sum of the number of bowel movements in a given week divided by the number of days with non-missing bowel movement frequency data. If more than 3 days of bowel movement data was missing in a given week, bowel movement frequency data was considered missing for that week.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24
Reported as:
Median · Bowel movements per day
Number of Bowel Movements Per Day Based on a 1-week Average up to Week 24
Bowel movements per dayPozelimab Injection
Baseline1.64 (0.5 to 3.4)
Week 11.13 (0.3 to 3.0)
Week 21.36 (0.7 to 3.4)
Week 31.43 (0.7 to 2.4)
Week 41.50 (0.8 to 2.6)
Week 51.57 (0.5 to 2.3)
Week 61.21 (0.6 to 3.0)
Week 71.21 (0.3 to 2.5)
Week 81.07 (0.2 to 2.3)
Week 91.00 (0.3 to 2.0)
Week 101.00 (0.5 to 1.7)
Week 111.00 (0.2 to 2.0)
Week 120.79 (0.0 to 1.9)
Week 130.93 (0.1 to 2.3)
Week 140.93 (0.3 to 2.1)
Week 151.07 (0.3 to 2.3)
Week 161.10 (0.4 to 2.0)
Week 171.13 (0.3 to 2.0)
Week 181.00 (0.0 to 1.9)
Week 191.00 (0.3 to 1.9)
Week 200.83 (0.2 to 2.1)
Week 211.00 (0.5 to 1.7)
Week 220.83 (0.4 to 1.7)
Week 230.86 (0.5 to 1.8)
Week 240.90 (0.3 to 2.0)
SecondaryNumber of Days Per Week With >=1 Bowel Movement of Loose/Watery Stool Consistency at Week 24

The number of days per week with \>=1 loose/watery bowel movement, is calculated each week of the study as the sum of the number of days with \>=1 loose/watery bowel movement in a given week divided by the number of days with non-missing stool consistency data and then multiplied by 7, is presented. If more than 3 days of stool consistency data was missing in a given week, stool consistency data was considered missing for that week.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24
Reported as:
Median · Days per week
Number of Days Per Week With >=1 Bowel Movement of Loose/Watery Stool Consistency at Week 24
Days per weekPozelimab Injection
Baseline2.00 (0.0 to 7.0)
Week 10.50 (0.0 to 5.0)
Week 20.00 (0.0 to 2.0)
Week 30.00 (0.0 to 3.0)
Week 40.00 (0.0 to 4.0)
Week 50.00 (0.0 to 5.0)
Week 61.20 (0.0 to 5.0)
Week 70.50 (0.0 to 2.8)
Week 80.50 (0.0 to 3.0)
Week 90.50 (0.0 to 3.0)
Week 100.00 (0.0 to 4.0)
Week 111.00 (0.0 to 2.3)
Week 120.00 (0.0 to 2.3)
Week 130.00 (0.0 to 4.0)
Week 141.58 (0.0 to 4.7)
Week 151.00 (0.0 to 7.0)
Week 160.00 (0.0 to 5.8)
Week 171.28 (0.0 to 5.6)
Week 180.50 (0.0 to 7.0)
Week 190.00 (0.0 to 5.0)
Week 200.00 (0.0 to 5.0)
Week 210.00 (0.0 to 6.0)
Week 220.00 (0.0 to 6.0)
Week 230.00 (0.0 to 6.0)
Week 240.00 (0.0 to 5.6)
SecondaryNumber of Participants With Abdominal Ascites at Week 24

The measurement of abdominal ascites (excess abdominal fluid) was based on abdominal circumference. Abdominal circumference was measured regardless of the physician's assessment of the presence or absence of ascites.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Abdominal Ascites at Week 24
ParticipantsPozelimab Injection
Number of Participants With Abdominal Ascites at Week 241
SecondaryAbsolute Value of Albumin at Specified Timepoints up to Week 24

Blood samples were collected from participants at defined time points for the assessment of albumin. Absolute value of albumin at specified timepoints was reported.

Time frame:
Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24
Reported as:
Mean · g/dL
Absolute Value of Albumin at Specified Timepoints up to Week 24
g/dLPozelimab Injection
Baseline2.160 ± 0.5296
Day 22.267 ± 0.4000
Week 13.311 ± 0.4485
Week 23.589 ± 0.4428
Week 34.025 ± 0.3955
Week 44.167 ± 0.3841
Week 64.411 ± 0.7026
Week 84.188 ± 0.3137
Week 104.322 ± 0.2279
Week 124.288 ± 0.2748
Week 144.363 ± 0.2615
Week 164.367 ± 0.3674
Week 184.344 ± 0.2555
Week 204.449 ± 0.2539
Week 224.422 ± 0.2906
Week 244.544 ± 0.2603
SecondaryAbsolute Values of Protein, and Immunoglobulin G (IgG) at Baseline and Week 24

Blood samples were collected from participants at defined time points for the assessment of protein and IgG. Absolutes values of protein and IgG measured as g/L at baseline and Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · g/L
Absolute Values of Protein, and Immunoglobulin G (IgG) at Baseline and Week 24
g/LPozelimab Injection
Protein at Baseline37.50 ± 6.996
Protein at Week 2472.22 ± 4.969
IgG at Baseline2.183 ± 0.9103
IgG at Week 2411.301 ± 2.0503
SecondaryAbsolute Values of Immunoglobulin (Ig), Immunoglobulin M (IgM), and Immunoglobulin A (IgA) at Baseline and Week 24

Blood samples were collected from participants at defined time points for the assessment of Ig, IgM and IgA. Absolute value of Ig, IgM and IgA measured as mg/dL at baseline and Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · mg/dL
Absolute Values of Immunoglobulin (Ig), Immunoglobulin M (IgM), and Immunoglobulin A (IgA) at Baseline and Week 24
mg/dLPozelimab Injection
Ig at Baseline318.2 ± 113.36
Ig at Week 241430.1 ± 263.36
IgM at Baseline52.9 ± 28.36
IgM at Week 24180.3 ± 74.81
IgA at Baseline47.0 ± 18.51
IgA at Week 24119.8 ± 52.46
SecondaryAbsolute Values of Vitamin B12 at Baseline and Week 24

Blood samples were collected from participants at defined time points for the assessment of vitamin B12. Absolute values of vitamin B12 at baseline and Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · picomoles per liter (pmol/L)
Absolute Values of Vitamin B12 at Baseline and Week 24
picomoles per liter (pmol/L)Pozelimab Injection
Baseline158.5 ± 52.32
Week 24383.1 ± 102.73
SecondaryAbsolute Values of Iron and Unsaturated Iron Binding Capacity at Baseline and Week 24

Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of unsaturated iron and unsaturated iron binding capacity measured as micromoles per liter (mcmol/L) at baseline and Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · mcmol/L
Absolute Values of Iron and Unsaturated Iron Binding Capacity at Baseline and Week 24
mcmol/LPozelimab Injection
Iron at Baseline3.40 ± 1.478
Iron at Week 247.38 ± 5.036
Unsaturated Binding Capacity at Baseline38.24 ± 12.357
Unsaturated Iron Binding Capacity at Week 2473.95 ± 12.049
SecondaryAbsolute Values of Vitamin B9 up to Week 24

Absolute Values of Vitamin B9 - Central Lab

Time frame:
Baseline up to Week 24
Reported as:
Mean · nanomoles per liter (nmol/L)
Absolute Values of Vitamin B9 up to Week 24
nanomoles per liter (nmol/L)Pozelimab Injection
Week 117.80 ± 15.017
Week 422.07 ± 14.342
Week 817.32 ± 8.042
Week 1217.89 ± 9.646
Week 1618.01 ± 10.610
Week 2019.91 ± 15.436
Week 2418.93 ± 6.538
SecondaryAbsolute Values of Ferritin at Baseline and Week 24

Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of ferritin was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · microgram per liter (mcg/L)
Absolute Values of Ferritin at Baseline and Week 24
microgram per liter (mcg/L)Pozelimab Injection
Baseline10.0 ± 5.90
Week 2412.0 ± 7.86
SecondaryAbsolute Values of Magnesium, Total Cholesterol, and Triglycerides at Week 24

Blood samples were collected from participants at defined time points for the assessment of magnesium, total cholesterol, and triglycerides. Absolute values of magnesium, total cholesterol, and triglycerides measured as mmol/L at baseline and Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Absolute Values of Magnesium, Total Cholesterol, and Triglycerides at Week 24
mmol/LPozelimab Injection
Magnesium at Baseline0.793 ± 0.0381
Magnesium at Week 240.858 ± 0.0245
Total Cholesterol at Baseline3.819 ± 0.8786
Total Cholesterol at Week 243.604 ± 0.3118
Triglycerides at Baseline2.033 ± 0.7946
Triglycerides at Week 241.094 ± 0.3745
SecondaryChange From Baseline in Alpha-1 Antitrypsin Levels in Stool at Week 12 and Week 24
Time frame:
Week 12, Week 24
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in Alpha-1 Antitrypsin Levels in Stool at Week 12 and Week 24
milligrams per deciliter (mg/dL)Pozelimab Injection
Change from Baseline to Week 12-527.80 ± 318.818
Change from Baseline to Week 24-463.71 ± 204.250
SecondaryChange From Baseline in Alpha-1 Antitrypsin Levels in Blood at Week 12 and Week 24
Time frame:
Week 12, Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Alpha-1 Antitrypsin Levels in Blood at Week 12 and Week 24
mg/dLPozelimab Injection
Change from Baseline to Week 12-57.8 ± 33.15
Change from Baseline to Week 24-43.4 ± 35.89
SecondaryPercentage of Participants With Active Disease at Baseline Who Maintained Disease Control

Measured by normalization of serum albumin, no worsening of facial or peripheral edema, increase in bowel movement, or increase in abdominal pain frequency, no increase in dose of permitted concomitant medication for the treatment of PLE at any time as described in the protocol

Time frame:
Weeks 12 to 48; Weeks 12 to 144; Weeks 24 to 48; Weeks 48 to 96; Weeks 96 to 144
Reported as:
Number · percentage of participants
Percentage of Participants With Active Disease at Baseline Who Maintained Disease Control
percentage of participantsPozelimab Injection
Weeks 12 to 48100
Weeks 12 to 144100
Weeks 24 to 48100
Weeks 48 to 96100
Weeks 96 to 144100
SecondaryChange From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale

The physician assessment of facial edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).

Time frame:
Baseline and Week 144
Reported as:
Mean · score on a scale
Change From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale
score on a scalePozelimab Injection
Change From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale-1.7 ± 0.87
SecondaryChange From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale

The physician assessment of peripheral edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).

Time frame:
Baseline and Week 144
Reported as:
Mean · score on a scale
Change From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale
score on a scalePozelimab Injection
Change From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale-1.7 ± 0.71
SecondaryChange From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale

Frequency of limitations is assessed on a 5-point Likert response scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse scored and linearly transformed to a 0 to 100 scale, where lower scores indicate more frequent problems with food and drink limitations.

Time frame:
Baseline and Week 144
Reported as:
Mean · score on a scale
Change From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale
score on a scalePozelimab Injection
Change From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale47.40 ± 36.653
SecondaryChange From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the PedsQL™ Generic Core Scales

Physical functioning, emotional functioning, social functioning, and school/work/studies functioning is assessed using a 5-point Likert scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse-scored and linearly transformed to a 0 to 100 scale, with higher scores indicating better HRQoL. The total scale score is computed as the sum of all the items over the number of items answered on individual scales. Subscale score is calculated as the sum of the items in the scale divided by the number of items answered in the scale.

Time frame:
Baseline and Week 144
Reported as:
Mean · score on a scale
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the PedsQL™ Generic Core Scales
score on a scalePozelimab Injection
Week 144 Change from Baseline Total score of PedsQL Core Score26.55 ± 17.023
Week 144 Change from Baseline Subscale score: Physical functioning14.45 ± 39.900
Week 144 Change from Baseline Subscale score: Emotional functioning26.3 ± 28.88
Week 144 Change from Baseline Subscale score: Social functioning30.6 ± 20.43
Week 144 Change from Baseline Subscale score: School functioning41.43 ± 19.518
SecondaryNumber of Participants With Albumin Infusion by 24 Week Periods
Time frame:
Weeks 0 to 24; Weeks 24 to 48; Weeks 48 to 72; Weeks 72 to 96; Weeks 96 to 120; Weeks 120 to 144
Reported as:
Count of participants · Participants
Number of Participants With Albumin Infusion by 24 Week Periods
ParticipantsPozelimab Injection
Weeks 0 to 241
Weeks 24 to 480
Weeks 48 to 720
Weeks 72 to 960
Weeks 96 to 1200
Weeks 120 to 1440
SecondaryChange From Baseline in Albumin Values
Time frame:
Baseline and Week 144
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline in Albumin Values
grams per deciliter (g/dL)Pozelimab Injection
Change From Baseline in Albumin Values2.400 ± 0.6103
SecondaryPercentage Change From Baseline in Albumin Values
Time frame:
Baseline and Week 144
Reported as:
Mean · percentage of change
Percentage Change From Baseline in Albumin Values
percentage of changePozelimab Injection
Percentage Change From Baseline in Albumin Values127.489 ± 81.0666
SecondaryTime to First Normalization for Albumin Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Albumin Values
daysPozelimab Injection
Time to First Normalization for Albumin Values15.5 (8 to 28)
SecondaryChange From Baseline in Protein Values
Time frame:
Baseline and Week 144
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Protein Values
grams per liter (g/L)Pozelimab Injection
Change From Baseline in Protein Values37.13 ± 10.789
SecondaryTime to First Normalization for Total Protein
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Total Protein
daysPozelimab Injection
Time to First Normalization for Total Protein22.0 (9 to 35)
SecondaryChange From Baseline in Immunoglobulin (Ig) Values
Time frame:
Baseline and Week 144
Reported as:
Mean · mg/dL
Change From Baseline in Immunoglobulin (Ig) Values
mg/dLPozelimab Injection
Change From Baseline in Immunoglobulin (Ig) Values1271.2 ± 261.91
SecondaryTime to First Normalization for Ig Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Ig Values
daysPozelimab Injection
Time to First Normalization for Ig Values341 (341 to 341)
SecondaryChange From Baseline in IgG Values
Time frame:
Baseline and Week 144
Reported as:
Mean · g/L
Change From Baseline in IgG Values
g/LPozelimab Injection
Change From Baseline in IgG Values10.626 ± 2.2486
SecondaryTime to First Normalization for IgG Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for IgG Values
daysPozelimab Injection
Time to First Normalization for IgG Values29.0 (8 to 29)
SecondaryChange From Baseline in IgM Values
Time frame:
Baseline and Week 144
Reported as:
Mean · mg/dL
Change From Baseline in IgM Values
mg/dLPozelimab Injection
Change From Baseline in IgM Values112.0 ± 51.21
SecondaryTime to First Normalization for IgM Values
Time frame:
Baseline up to Week 44
Reported as:
Median · days
Time to First Normalization for IgM Values
daysPozelimab Injection
Time to First Normalization for IgM Values1 (1 to 9)
SecondaryChange From Baseline in IgA Values
Time frame:
Baseline and Week 144
Reported as:
Mean · mg/dL
Change From Baseline in IgA Values
mg/dLPozelimab Injection
Change From Baseline in IgA Values96.7 ± 28.78
SecondaryTime to First Normalization for IgA Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for IgA Values
daysPozelimab Injection
Time to First Normalization for IgA Values1 (1 to 9)
SecondaryChange From Baseline in Vitamin B12 Values
Time frame:
Baseline and Week 144
Reported as:
Mean · picomoles per liter (pmol/L)
Change From Baseline in Vitamin B12 Values
picomoles per liter (pmol/L)Pozelimab Injection
Change From Baseline in Vitamin B12 Values138.8 ± 56.07
SecondaryTime to First Normalization for Vitamin B12 Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Vitamin B12 Values
daysPozelimab Injection
Time to First Normalization for Vitamin B12 Values8 (1 to 8)
SecondaryChange From Baseline in Vitamin B9 (Folate) Values
Time frame:
Baseline and Week 144
Reported as:
Mean · nanomole per liter (nmol/L)
Change From Baseline in Vitamin B9 (Folate) Values
nanomole per liter (nmol/L)Pozelimab Injection
Change From Baseline in Vitamin B9 (Folate) Values2.92 ± 10.241
SecondaryTime to First Normalization for Vitamin B9 (Folate) Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Vitamin B9 (Folate) Values
daysPozelimab Injection
Time to First Normalization for Vitamin B9 (Folate) Values1 (1 to 8)
SecondaryChange From Baseline in Iron Values
Time frame:
Baseline and Week 144
Reported as:
Mean · micromole/liter (umol/L)
Change From Baseline in Iron Values
micromole/liter (umol/L)Pozelimab Injection
Change From Baseline in Iron Values7.82 ± 4.091
SecondaryTime to First Normalization for Iron Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Iron Values
daysPozelimab Injection
Time to First Normalization for Iron Values97.5 (1 to 337)
SecondaryChange From Baseline in Unsaturated Iron Binding Capacity
Time frame:
Baseline and Week 144
Reported as:
Mean · umol/L
Change From Baseline in Unsaturated Iron Binding Capacity
umol/LPozelimab Injection
Change From Baseline in Unsaturated Iron Binding Capacity16.20 ± 13.811
SecondaryTime to First Normalization for Unsaturated Iron Binding Capacity
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Unsaturated Iron Binding Capacity
daysPozelimab Injection
Time to First Normalization for Unsaturated Iron Binding Capacity1 (1 to 56)
SecondaryChange From Baseline in Ferritin Values
Time frame:
Baseline and Week 144
Reported as:
Mean · microgram per liter (ug/L)
Change From Baseline in Ferritin Values
microgram per liter (ug/L)Pozelimab Injection
Change From Baseline in Ferritin Values32.0 ± 23.67
SecondaryTime to First Normalization for Ferritin Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Ferritin Values
daysPozelimab Injection
Time to First Normalization for Ferritin Values28 (1 to 505)
SecondaryChange From Baseline in Magnesium Values
Time frame:
Baseline and Week 144
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Magnesium Values
millimoles per liter (mmol/L)Pozelimab Injection
Change From Baseline in Magnesium Values0.083 ± 0.0606
SecondaryTime to First Normalization for Magnesium Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Magnesium Values
daysPozelimab Injection
Time to First Normalization for Magnesium Values1 (1 to 2)
SecondaryChange From Baseline in Fasting Cholesterol Values
Time frame:
Baseline and Week 144
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Cholesterol Values
mmol/LPozelimab Injection
Change From Baseline in Fasting Cholesterol Values-0.072 ± 0.7299
SecondaryTime to First Normalization for Fasting Cholesterol Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Fasting Cholesterol Values
daysPozelimab Injection
Time to First Normalization for Fasting Cholesterol Values1 (1 to 29)
SecondaryChange From Baseline in Fasting Triglycerides Values
Time frame:
Baseline and Week 144
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Triglycerides Values
mmol/LPozelimab Injection
Change From Baseline in Fasting Triglycerides Values-0.710 ± 0.9086
SecondaryTime to First Normalization for Fasting Triglycerides Values
Time frame:
Baseline up to Week 144
Reported as:
Median · days
Time to First Normalization for Fasting Triglycerides Values
daysPozelimab Injection
Time to First Normalization for Fasting Triglycerides Values4 (1 to 57)
SecondaryNumber of Participants Who Used Concomitant Medication
Time frame:
Baseline up to Week 144
Reported as:
Count of participants · Participants
Number of Participants Who Used Concomitant Medication
ParticipantsPozelimab Injection
Number of Participants Who Used Concomitant Medication10
SecondaryNumber of Hospitalization Days by 24 Week Period
Time frame:
Weeks 0 to 24; Weeks 24 to 48; Weeks 48 to 72; Weeks 72 to 96; Weeks 96 to 120; Weeks 120 to 144
Reported as:
Median · days
Number of Hospitalization Days by 24 Week Period
daysPozelimab Injection
Weeks 0 to 240.0 (0 to 4)
Weeks 24 to 480.0 (0 to 0)
Weeks 48 to 720.0 (0 to 0)
Weeks 72 to 960.0 (0 to 0)
Weeks 96 to 1200.0 (0 to 2)
Weeks 120 to 1440.0 (0 to 0)
SecondaryChange From Baseline in Body Weight Z-Score

Weight-for-age z-score compares a participant's weight to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Body weight z-score, regardless of magnitude, represents catch-up growth.

Time frame:
Baseline and Week 144
Reported as:
Mean · z-score
Change From Baseline in Body Weight Z-Score
z-scorePozelimab Injection
Change From Baseline in Body Weight Z-Score0.924 ± 0.7529
SecondaryChange From Baseline in Height Z-Score

Height-for-age z-score compares a participant's height to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Any increase in height z-score, regardless of magnitude, represents catch-up growth.

Time frame:
Baseline and Week 144
Reported as:
Mean · z-score
Change From Baseline in Height Z-Score
z-scorePozelimab Injection
Change From Baseline in Height Z-Score1.079 ± 0.6469
SecondaryChange From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50)
Time frame:
Baseline and Week 144
Reported as:
Mean · international units/milliliter (IU/mL)
Change From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50)
international units/milliliter (IU/mL)Pozelimab Injection
Change From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50)-241.6 ± 39.79
SecondaryConcentrations of Total Pozelimab in Serum
Time frame:
Baseline up to Week 164
Reported as:
Mean · mg/L
Concentrations of Total Pozelimab in Serum
mg/LPozelimab Injection
Week 1182 ± 68.9
Week 2185 ± 103
Week 4227 ± 110
Week 6268 ± 106
Week 8306 ± 111
Week 12341 ± 115
Week 16402 ± 141
Week 20418 ± 136
Week 24421 ± 129
Week 36467 ± 127
Week 48517 ± 142
Week 72492 ± 131
Week 96461 ± 115
Week 144430 ± 134
Week 145NA ± NA
Week 146NA ± NA
Week 164410 ± 104
SecondaryNumber of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab
Time frame:
Baseline up to Week 164
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab
ParticipantsPozelimab Injection
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab0

Adverse events

Collected over From signing of informed consent up to 164 weeks (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pozelimab Injection0/10 (0%)5/10 (50%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventPozelimab Injection
VomitingGastrointestinal disorders2/10
DehydrationMetabolism and nutrition disorders1/10
Abdominal painGastrointestinal disorders1/10
Head injuryInjury, poisoning and procedural complications1/10
Upper limb fractureInjury, poisoning and procedural complications1/10
Urinary tract infectionInfections and infestations1/10
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPozelimab Injection
Abdominal painGastrointestinal disorders4/10
VomitingGastrointestinal disorders4/10
NasopharyngitisInfections and infestations3/10
Upper respiratory tract infectionInfections and infestations3/10
RhinitisInfections and infestations2/10
AcarodermatitisInfections and infestations2/10
PyrexiaGeneral disorders2/10
HeadacheNervous system disorders2/10
COVID-19Infections and infestations2/10
ContusionInjury, poisoning and procedural complications2/10

Baseline characteristics

The full analysis set (FAS) included all enrolled participants who received the study drug.

Age, Continuous
Age, Continuous(years)Pozelimab Injection
Mean9.3 ± 4.88
Sex: Female, Male
Sex: Female, Male(Participants)Pozelimab Injection
Female6
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pozelimab Injection
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pozelimab Injection
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported1
08

Study locations

3 sites
  • Regeneron Research Site
    Bethesda, Maryland 20892, United States
  • Regeneron Research Site
    Pathum Wan, Bangkok 10330, Thailand
  • Regeneron Research Site
    Istanbul, 34890, Turkey (Türkiye)
09

References and documents

Publications

  • Litcher-Kelly L, Ozen A, Ollis S, Feldman HB, Yaworsky A, Medrano P, Chongsrisawat V, Perlee L, Walker M, Pradeep S, Turner-Bowker DM, Kurolap A, Adiv OE, Lenardo MJ, Harari OA, Jalbert JJ. The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition. Orphanet J Rare Dis. 2025 Feb 11;20(1):68. doi: 10.1186/s13023-024-03436-y. PubMed 39934837 ↗
  • Litcher-Kelly L, Ozen A, Ollis S, Feldman HB, Yaworsky A, Medrano P, Chongsrisawa V, Brackin T, Perlee L, Walker M, Pradeep S, Lenardo MJ, Harari OA, Jalbert JJ. Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments. Orphanet J Rare Dis. 2024 Aug 8;19(1):290. doi: 10.1186/s13023-024-03277-9. PubMed 39118150 ↗
  • Ozen A, Chongsrisawat V, Sefer AP, Kolukisa B, Jalbert JJ, Meagher KA, Brackin T, Feldman HB, Baris S, Karakoc-Aydiner E, Ergelen R, Fuss IJ, Moorman H, Suratannon N, Suphapeetiporn K, Perlee L, Harari OA, Yancopoulos GD, Lenardo MJ; Pozelimab CHAPLE Working Group. Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study. Lancet. 2024 Feb 17;403(10427):645-656. doi: 10.1016/S0140-6736(23)02358-9. Epub 2024 Jan 23. PubMed 38278170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Nov 2021, 21 months.

Results were first posted in Oct 2023, 1 year 11 months after primary completion. A results delay was requested in Nov 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2019
First posted
Dec 24, 2019
StartActual
Jan 27, 2020
Primary completionActual
Nov 9, 2021
CompletionActual
May 2, 2024
Results delay requested
Nov 8, 2022
Results first posted
Oct 30, 2023
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04209634
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Jan 27, 2020
Primary completion
Nov 9, 2021
Completion
May 2, 2024
Results posted
Oct 30, 2023
Last update
Aug 29, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion